Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

BOTANICAL-DERIVED DRUG DISCOVERY FOR CANCER THERAPY

Award Number: R43CA114876
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2008
PERIOD OF PERFORMANCE END DATE: 09/21/2009

Group Awards By:

View Award Description

BOTANICAL-DERIVED DRUG DISCOVERY FOR CANCER THERAPY - DESCRIPTION (provided by applicant): In a screen for naturally occurring angiogenic inhibitors, we have identified an extract from the plant Livistona chinensis, which has potent anti-angiogenic and anti-tumor activity and is non-toxic in mice. To our knowledge, ours is the first publication in the English literature on this extract from Livistona chinensis. We hypothesize that the Livistona extract inhibits tumorigenesis and angiogenesis, and that the effects exerted by many one or more active components in Livistona chinensis may be critical to the chemopreventive or chemotherapeutic application of this extract. In this innovative research proposal, we will identify the active ingredient(s) in the extract based on the in vitro anti-proliferative and antiangiogenic assays; investigate whether these components have an effect when used in in-vivo testing. Our specific aims for Phase 1 are as follows: Aim 1: To isolate and identify the active component(s) from the plant Livistona chinensis using a variety of chemical and analytical techniques, including extraction, chromatographic separation, nuclear magnetic resonance, photo diode array, infrared and high resolution mass spectrometry. Aim 2: To test the effect of cach active component on in vitro breast tumorigenicity and antiogenesis assays. The active components will be tested in breast tumor xenograft models. Furthermore, we will begin to investigate the mechanism(s) of action exerted by the active compound(s). Considering the observed low toxicity, oral availability, stability, and potent pharmacologic activity in our animal models from the plant extract, we see this research of particular high value in the efforts to develop novel effective therapies against breast cancer, and possibly other solid tumors as well. Public Health Relevance: This Public Health Relevance is not available.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2008 ( Subtotal = $130,207 )
2008	2008	BCN BIOSCIENCES LLC	2275 EAST FOOTHILL BOULEVARD	PASADENA	CA	91107	LOS ANGELES	USA	Cancer Treatment Research	000	1	9/22/2008	NEW	$130,207
														Subtotal = $130,207

Grand Total All Awards = $130,207

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BOTANICAL-DERIVED DRUG DISCOVERY FOR CANCER THERAPY

Award Number: R43CA114876

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2008

PERIOD OF PERFORMANCE END DATE: 09/21/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer